Radiation-induced apoptosis in human lymphocytes and lymphoma cells critically relies on the up-regulation of CD95/Fas/APO-1 ligand. 1998

C Belka, and P Marini, and W Budach, and K Schulze-Osthoff, and F Lang, and E Gulbins, and M Bamberg
Department of Radiation Oncology, University of Tuebingen, Germany.

Ionizing radiation is known to induce death by apoptosis in malignant and nonmalignant human lymphocytes. The mechanism which initiates the induction of apoptosis has not been identified. Here we demonstrate that a radiation-induced up-regulation of CD95/Fas/APO-1 ligand (CD95-L) is involved in the induction of apoptosis in lymphocytes and lymphoma cells. Using antibodies against CD95-L, we detected a rapid and persistent up-regulation of CD95-L in Jurkat cells and blood lymphocytes after irradiation. Blocking of interactions between CD95/Fas/APO-1 and CD95-L with inhibitory antibodies reduces apoptosis after irradiation. The hypothesis that an interaction between CD95 and CD95-L is involved in radiation-induced apoptosis is supported by the finding that only peripheral blood lymphocytes that are stimulated with interleukin 2 for 5 days and thus are rendered sensitive to CD95-L show pronounced levels of apoptosis in response to low radiation doses, whereas resting peripheral blood lymphocytes show very low levels of apoptosis after treatment with CD95-L and radiation. The finding that the caspase FLICE is degraded proteolytically after irradiation and the observation of a radiation-induced CD95 receptor capping confirm the functional activation of the CD95 receptor.

UI MeSH Term Description Entries
D008214 Lymphocytes White blood cells formed in the body's lymphoid tissue. The nucleus is round or ovoid with coarse, irregularly clumped chromatin while the cytoplasm is typically pale blue with azurophilic (if any) granules. Most lymphocytes can be classified as either T or B (with subpopulations of each), or NATURAL KILLER CELLS. Lymphoid Cells,Cell, Lymphoid,Cells, Lymphoid,Lymphocyte,Lymphoid Cell
D008223 Lymphoma A general term for various neoplastic diseases of the lymphoid tissue. Germinoblastoma,Lymphoma, Malignant,Reticulolymphosarcoma,Sarcoma, Germinoblastic,Germinoblastic Sarcoma,Germinoblastic Sarcomas,Germinoblastomas,Lymphomas,Lymphomas, Malignant,Malignant Lymphoma,Malignant Lymphomas,Reticulolymphosarcomas,Sarcomas, Germinoblastic
D008562 Membrane Glycoproteins Glycoproteins found on the membrane or surface of cells. Cell Surface Glycoproteins,Surface Glycoproteins,Cell Surface Glycoprotein,Membrane Glycoprotein,Surface Glycoprotein,Glycoprotein, Cell Surface,Glycoprotein, Membrane,Glycoprotein, Surface,Glycoproteins, Cell Surface,Glycoproteins, Membrane,Glycoproteins, Surface,Surface Glycoprotein, Cell,Surface Glycoproteins, Cell
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D015854 Up-Regulation A positive regulatory effect on physiological processes at the molecular, cellular, or systemic level. At the molecular level, the major regulatory sites include membrane receptors, genes (GENE EXPRESSION REGULATION), mRNAs (RNA, MESSENGER), and proteins. Receptor Up-Regulation,Upregulation,Up-Regulation (Physiology),Up Regulation
D017209 Apoptosis A regulated cell death mechanism characterized by distinctive morphologic changes in the nucleus and cytoplasm, including the endonucleolytic cleavage of genomic DNA, at regularly spaced, internucleosomal sites, i.e., DNA FRAGMENTATION. It is genetically programmed and serves as a balance to mitosis in regulating the size of animal tissues and in mediating pathologic processes associated with tumor growth. Apoptosis, Extrinsic Pathway,Apoptosis, Intrinsic Pathway,Caspase-Dependent Apoptosis,Classic Apoptosis,Classical Apoptosis,Programmed Cell Death,Programmed Cell Death, Type I,Apoptoses, Extrinsic Pathway,Apoptoses, Intrinsic Pathway,Apoptosis, Caspase-Dependent,Apoptosis, Classic,Apoptosis, Classical,Caspase Dependent Apoptosis,Cell Death, Programmed,Classic Apoptoses,Extrinsic Pathway Apoptoses,Extrinsic Pathway Apoptosis,Intrinsic Pathway Apoptoses,Intrinsic Pathway Apoptosis
D053222 Fas Ligand Protein A transmembrane protein belonging to the tumor necrosis factor superfamily that was originally discovered on cells of the lymphoid-myeloid lineage, including activated T-LYMPHOCYTES and NATURAL KILLER CELLS. It plays an important role in immune homeostasis and cell-mediated toxicity by binding to the FAS RECEPTOR and triggering APOPTOSIS. Antigens, CD178,CD178 Antigens,Tumor Necrosis Factor Ligand Superfamily Member 6,CD178 Antigen,CD95 Antigen Ligand,CD95 Ligand,CD95L,Fas Ligand,Fas Ligand (FasL),FasL Protein,TNF Superfamily, Member 6,Antigen, CD178
D019014 fas Receptor A tumor necrosis factor receptor subtype found in a variety of tissues and on activated LYMPHOCYTES. It has specificity for FAS LIGAND and plays a role in regulation of peripheral immune responses and APOPTOSIS. Multiple isoforms of the protein exist due to multiple ALTERNATIVE SPLICING. The activated receptor signals via a conserved death domain that associates with specific TNF RECEPTOR-ASSOCIATED FACTORS in the CYTOPLASM. Mutations in the CD95 gene are associated with cases of autoimmune lymphoproliferative syndrome. APO-1 Antigen,Antigens, CD95,CD95 Antigens,Receptors, fas,Tumor Necrosis Factor Receptor Superfamily, Member 6,fas Antigens,fas Receptors,CD95 Antigen,Fas Cell Surface Death Receptor,TNFRSF6 Receptor,fas Antigen,APO 1 Antigen,Receptor, TNFRSF6,Receptor, fas

Related Publications

C Belka, and P Marini, and W Budach, and K Schulze-Osthoff, and F Lang, and E Gulbins, and M Bamberg
July 2001, Arthritis and rheumatism,
C Belka, and P Marini, and W Budach, and K Schulze-Osthoff, and F Lang, and E Gulbins, and M Bamberg
May 1998, Cancer research,
C Belka, and P Marini, and W Budach, and K Schulze-Osthoff, and F Lang, and E Gulbins, and M Bamberg
December 2008, Biochemical pharmacology,
C Belka, and P Marini, and W Budach, and K Schulze-Osthoff, and F Lang, and E Gulbins, and M Bamberg
August 1997, Cancer research,
C Belka, and P Marini, and W Budach, and K Schulze-Osthoff, and F Lang, and E Gulbins, and M Bamberg
May 1997, Biochemical Society transactions,
C Belka, and P Marini, and W Budach, and K Schulze-Osthoff, and F Lang, and E Gulbins, and M Bamberg
January 1999, Cancer research,
C Belka, and P Marini, and W Budach, and K Schulze-Osthoff, and F Lang, and E Gulbins, and M Bamberg
June 1998, British journal of haematology,
C Belka, and P Marini, and W Budach, and K Schulze-Osthoff, and F Lang, and E Gulbins, and M Bamberg
May 1996, Nature medicine,
C Belka, and P Marini, and W Budach, and K Schulze-Osthoff, and F Lang, and E Gulbins, and M Bamberg
July 1997, The Journal of biological chemistry,
C Belka, and P Marini, and W Budach, and K Schulze-Osthoff, and F Lang, and E Gulbins, and M Bamberg
January 2001, Journal of clinical immunology,
Copied contents to your clipboard!